M. Nesheim

发表

Temporal changes in factors associated with neutrophil elastase and coagulation in intensive care patients with a biphasic waveform and disseminated intravascular coagulation

A. Day, C. Toh, J. Samis, 2004, Journal of thrombosis and haemostasis : JTH.

Activated thrombin‐activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation

A. Giles, M. Nesheim, P. Kim, 2008, Journal of thrombosis and haemostasis : JTH.

Factor Xa is highly protected from antithrombin–fondaparinux and antithrombin–enoxaparin when incorporated into the prothrombinase complex

A. Ward, M. Nesheim, N. Brufatto, 2003, Journal of thrombosis and haemostasis : JTH.

Progressive development of a thrombin inhibitor binding site.

K. Mann, L. Hibbard, M. Nesheim, 1982, Biochemistry.

Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide.

K. Mann, F. G. Prendergast, M. Nesheim, 1979, Biochemistry.

A simple rate law that describes the kinetics of the heparin-catalyzed reaction between antithrombin III and thrombin.

M. Nesheim, 1983, The Journal of biological chemistry.

Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor*

J. Morser, M. Nesheim, L. Bajzar, 1998, The Journal of Biological Chemistry.

The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.

M. Nesheim, L. Bajzar, P. Tracy, 1996, Blood.

Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

M. Nesheim, L. Bajzar, R. Manuel, 1995, The Journal of Biological Chemistry.

Structural changes in the protease domain of prothrombin upon activation as assessed by N-bromosuccinimide modification of tryptophan residues in prethrombin-2 and thrombin.

M. Nesheim, W. Stevens, 1993, Biochemistry.

Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C.

K. Mann, W. Kisiel, M. Nesheim, 1982, The Journal of biological chemistry.

Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2

E. Pryzdial, M. Nesheim, Erica A. Peterson, 2003, Journal of Cell Science.

TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

J. Morser, M. Nesheim, L. Bajzar, 1996, The Journal of Biological Chemistry.

A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.

M. Boffa, M. Koschinsky, R. Bertina, 2001, Blood.

Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

M. Boffa, M. Koschinsky, M. Rahman, 2002, The Journal of Biological Chemistry.

Fluorescence Properties and Functional Roles of Tryptophan Residues 60d, 96, 148, 207, and 215 of Thrombin*

R. MacGillivray, Z. Jia, Z. Jia, 2000, The Journal of Biological Chemistry.

The kinetics of activation of normal and gamma-carboxyglutamic acid-deficient prothrombins.

K. Mann, M. Nesheim, O. Malhotra, 1985, The Journal of biological chemistry.

Alpha 2-macroglobulin binds and inhibits activated protein C.

A. Giles, C. Toh, M. Nesheim, 1991, Blood.

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

M. Nesheim, J. Willemse, D. Hendriks, 2009, Journal of thrombosis and haemostasis : JTH.

The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets.

A. Giles, M. Nesheim, R. Kaufman, 1991, The Journal of biological chemistry.

The kinetics and cofactor dependence of the two cleavages involved in prothrombin activation.

K. Mann, M. Nesheim, 1983, The Journal of biological chemistry.

Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

P. A. von dem Borne, J. Meijers, M. Nesheim, 1997, The Journal of clinical investigation.

On the Existence of Platelet Receptors for Factor V(a) and Factor VIII(a)

M. Nesheim, G. Côté, E. Furmaniak-Kazmierczak, 1993, Thrombosis and Haemostasis.

Proteolytic alterations of factor Va bound to platelets.

K. Mann, M. Nesheim, P. Tracy, 1983, The Journal of biological chemistry.

A Control Switch for Prothrombinase

M. Nesheim, P. Kim, M. Kalafatis, 2006, Journal of Biological Chemistry.

Identification and Characterization of Two Thrombin-activatable Fibrinolysis Inhibitor Isoforms

M. Nagashima, J. Morser, M. Nesheim, 1998, Thrombosis and Haemostasis.

Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C.

A. Giles, F. Taylor, A. Chang, 1992, Blood.

Elements of the Primary Structure of Thrombomodulin Required for Efficient Thrombin-activable Fibrinolysis Inhibitor Activation*

Weiqi Wang, M. Nagashima, J. Morser, 2000, The Journal of Biological Chemistry.

Amino Acid Residues in the P6-P′3 Region of Thrombin-activable Fibrinolysis Inhibitor (TAFI) Do Not Determine the Thrombomodulin Dependence of TAFI Activation*

M. Nagashima, J. Morser, M. Nesheim, 2002, The Journal of Biological Chemistry.

Soluble thrombomodulin partially corrects the premature lysis defect in FVIII‐deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor

J. Foley, M. Nesheim, 2009, Journal of thrombosis and haemostasis : JTH.

Coagulation factors V and VIII and ceruloplasmin constitute a family of structurally related proteins.

K. Mann, R. Jernigan, R. Hewick, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Mathematical simulation of prothrombinase.

K. Mann, R. Tracy, M. Nesheim, 1992, Methods in enzymology.

Long-term effects of estrogen on avian liver: estrogen-inducible switch in expression of nuclear, hormone-binding proteins

R. Haché, R. Deeley, M. Nesheim, 1987, Molecular and cellular biology.

Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis

F. Taylor, M. Nesheim, P. Kim, 2012, Journal of Thrombosis and Thrombolysis.

HISTORICAL SKETCH: The discovery of TAFI

M. Nesheim, L. Bajzar, 2005, Journal of thrombosis and haemostasis : JTH.

Inhibition of Plasminogen Activation by Lipoprotein(a)

M. Boffa, M. Koschinsky, S. Marcovina, 2003, Journal of Biological Chemistry.

A Ligand-induced Conformational Change in Apolipoprotein(a) Enhances Covalent Lp(a) Formation*

M. Koschinsky, B. Webb, M. Nesheim, 2003, The Journal of Biological Chemistry.

Incorporation of Factor Va into Prothrombinase Is Required for Coordinated Cleavage of Prothrombin by Factor Xa*

M. Nesheim, P. Kim, M. Kalafatis, 2005, Journal of Biological Chemistry.

Analysis of the Kinetics of Prothrombin Activation and Evidence That Two Equilibrating Forms of Prothrombinase Are Involved in the Process*

M. Nesheim, N. Brufatto, 2003, The Journal of Biological Chemistry.

Mechanism of potentiation of antithrombin III [AT-III] inhibition by sulfated xylans.

M. Nesheim, V. Doctor, A. Campbell, 1987, Thrombosis research.

Further Evidence for Two Functional Forms of Prothrombinase Each Specific for Either of the Two Prothrombin Activation Cleavages*

M. Nesheim, P. Kim, 2007, Journal of Biological Chemistry.

Channeling During Prothrombin Activation*

M. Nesheim, L. Bajzar, D. Boskovic, 2001, The Journal of Biological Chemistry.

Platelet factor Xa receptor.

K. Mann, M. Nesheim, P. Tracy, 1992, Methods in enzymology.

Chapter 2A Nonenzymatic cofactors: factor V*

K. Mann, M. Nesheim, P. Tracy, 1986 .

Assembly of the prothrombinase complex.

K. Mann, L. Hibbard, J. Bloom, 1982, Biophysical journal.

The Use of Prothrombin(S525C) Labeled with Fluorescein to Directly Study the Inhibition of Prothrombinase by Antithrombin during Prothrombin Activation*

M. Nesheim, N. Brufatto, 2001, The Journal of Biological Chemistry.

Factor V Is Complexed with Multimerin in Resting Platelet Lysates and Colocalizes with Multimerin in Platelet α-Granules (*)

J. Kelton, D. Bainton, M. Nesheim, 1995, The Journal of Biological Chemistry.

Prothrombinase Components Can Accelerate Tissue Plasminogen Activator-catalyzed Plasminogen Activation (*)

E. Pryzdial, M. Nesheim, Laszlo Bajzr, 1995, The Journal of Biological Chemistry.

Coagulation factor Va is an actin filament binding and cross-linking protein.

M. Nesheim, G. Côté, E. Furmaniak-Kazmierczak, 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Pathologic Fibrinolysis as a Cause of Clinical Bleeding

A. Giles, F. Taylor, W. Dzik, 1990, Seminars in thrombosis and hemostasis.

Isolation and study of an acquired inhibitor of human coagulation factor V.

T. L. Cole, K. Mann, J. Houston, 1986, The Journal of clinical investigation.

Coordinate binding of factor Va and factor Xa to the unstimulated platelet.

K. Mann, M. Nesheim, P. Tracy, 1981, The Journal of biological chemistry.

Monoclonal antibodies to human coagulation factor V and factor Va.

K. Mann, J. Katzmann, M. Nesheim, 1983, Blood.

Monoclonal antibodies to human coagulation factor V and factor Va

K. Mann, J. Katzmann, M. Nesheim, 1983 .

The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets.

A. Giles, M. Nesheim, R. Kaufman, 1988, The Journal of biological chemistry.

The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation.

M. Nesheim, L. Bajzar, 1993, The Journal of biological chemistry.

The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system.

M. Nesheim, J. Fredenburgh, L. Bajzar, 1990, The Journal of biological chemistry.

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.

Catalysis of covalent Lp(a) assembly: evidence for an extracellular enzyme activity that enhances disulfide bond formation.

M. Koschinsky, M. Nesheim, L. Becker, 2006, Biochemistry.

Thrombin activatable fibrinolysis inhibitor activation and bleeding in haemophilia A

G. Rivard, J. Foley, M. Nesheim, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease

S. Lipson, M. Nesheim, P. Kim, 2007, Journal of thrombosis and haemostasis : JTH.

Thrombin and fibrinolysis.

M. Nesheim, 2003, Chest.

Differential Signaling of Cysteinyl Leukotrienes and a Novel Cysteinyl Leukotriene Receptor 2 (CysLT2) Agonist, N-Methyl-Leukotriene C4, in Calcium Reporter and β Arrestin Assays

R. Stocco, M. Abramovitz, C. Funk, 2011, Molecular Pharmacology.

Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.

T. Cooke, A. Giles, M. Nesheim, 1994, The Journal of clinical investigation.

Inhibition of Plasminogen Activation by Lipoprotein(a): Critical Domains in Apolipoprotein(a) and Mechanism of Inhibition on Fibrin and Degraded Fibrin Surfaces

M. Boffa, M. Koschinsky, S. Marcovina, 2003 .

Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation.

M. Koschinsky, M. Nesheim, W. Sangrar, 1995, Biochemistry.

The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.

G. Larsen, M. Nesheim, J. Fredenburgh, 1990, The Journal of biological chemistry.

Modulation of Fibrin Cofactor Activity in Plasminogen Activation

M. Boffa, Wei Wang, A. Horrevoets, 2001, Annals of the New York Academy of Sciences.

A Kinetic Analysis of the Tissue Plasminogen Activator and DSPAα1 Cofactor Activities of Untreated and TAFIa-treated Soluble Fibrin Degradation Products of Varying Size*

M. Nesheim, John B. Walker, J. Walker, 2001, The Journal of Biological Chemistry.

The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface.

M. Boffa, M. Koschinsky, B. Gabel, 1997, Biochemistry.

A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 Domain*

A. Horrevoets, H. Pannekoek, M. Nesheim, 1997, The Journal of Biological Chemistry.

Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro.

M. Nesheim, J. Fredenburgh, 1992, The Journal of biological chemistry.

Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function.

A. Giles, E. Kam, J. Samis, 1998, Blood.

A unique function for LRP‐1: a component of a two‐receptor system mediating specific endocytosis of plasma‐derived factor V by megakaryocytes

D. Strickland, M. Nesheim, N. Meisler, 2008, Journal of thrombosis and haemostasis : JTH.

Differentiation of enzyme and substrate binding in the prothrombinase complex.

K. Mann, M. Nesheim, M. Tucker, 1983, Biochemistry.

Assembly of the prothrombinase complex in the absence of prothrombin.

K. Mann, M. Nesheim, S. Eid, 1981, The Journal of biological chemistry.

Lipoprotein-complexed C-reactive protein and the biphasic transmittance waveform in critically ill patients.

M. Koschinsky, A. Giles, R. Wenstone, 2002, Blood reviews.

Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin(desF1)

R. MacGillivray, J. Morser, J. Samis, 1997, The Journal of Biological Chemistry.

Studies of the role of factor Va in the factor Xa-catalyzed activation of prothrombin, fragment 1.2-prethrombin-2, and dansyl-L-glutamyl-glycyl-L-arginine-meizothrombin in the absence of phospholipid.

A. Giles, M. Nesheim, D. Boskovic, 1990, The Journal of biological chemistry.

The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction.

K. Mann, M. Nesheim, S. Krishnaswamy, 1986, The Journal of biological chemistry.

Proteolytic processing of human coagulation factor IX by plasmin.

A. Giles, J. Samis, M. Nesheim, 2000, Blood.

Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis

M. Nesheim, M. Schneider, 2003, Journal of thrombosis and haemostasis : JTH.

Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B).

M. Boffa, M. Koschinsky, M. Nesheim, 1999, Biochemistry.

Monoclonal antibodies selective for the functional states of bovine factor V and factor Va.

K. Mann, J. Katzmann, M. Nesheim, 1982, Thrombosis research.

Factor V cleavage and inactivation are temporally associated with elevated elastase during experimental sepsis

F. Taylor, J. Samis, K. Stewart, 2007, Journal of thrombosis and haemostasis : JTH.

Human Neutrophil Elastase Activates Human Factor V but Inactivates Thrombin-Activated Human Factor V

A. Giles, J. Samis, M. Nesheim, 1997 .

Lipid mobility in the assembly and expression of the activity of the prothrombinase complex.

P. J. Callahan, K. Mann, Deborah L. Higgins, 1985, The Journal of biological chemistry.

Molecular weight of undegraded plasma factor V.

K. Mann, M. Nesheim, P. Tracy, 1981, Biochemistry.

Factor V.

K. Mann, J. Katzmann, M. Nesheim, 1981, Methods in enzymology.

Thrombin-activatable fibrinolysis inhibitor aka procarboxypeptidase U

M. Nesheim, D. Hendriks, J. Leurs, 2006 .

The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin*

M. Nesheim, John B. Walker, J. Walker, 1999, The Journal of Biological Chemistry.

A qualitative and quantitative analysis of the activation and inactivation of protein C in vivo in a primate model.

A. Giles, M. Nesheim, H. Hoogendoorn, 1990, Blood.

A combination of factor Xa and phosphatidylcholine‐phosphatidylserine vesicles bypasses factor VIII in vivo

K. Mann, A. Giles, M. Nesheim, 1988, British journal of haematology.

Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.

K. Mann, A. Giles, M. Nesheim, 1984, The Journal of clinical investigation.

Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein

C. Toh, C. Downey, M. Nesheim, 2004, Thrombosis and Haemostasis.

The Fibrinolytic Potential of the Normal Primate following the Generation of Thrombin In Vivo

A. Giles, M. Nesheim, D. Stump, 1990, Thrombosis and Haemostasis.

Increased Lipoprotein ( a ) levels are not a steady prothrombotic defect

M. Boffa, M. Koschinsky, R. Bertina, 2001 .

Molecular analysis of the human thrombin‐activatable fibrinolysis inhibitor gene promoter

M. Boffa, M. Koschinsky, Nazareth Bastajian, 2007, British journal of haematology.

Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor

M. Boffa, M. Koschinsky, M. Nesheim, 2004, Journal of thrombosis and haemostasis : JTH.

Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders.

M. Boffa, M. Koschinsky, M. Nesheim, 2001, Current drug targets. Cardiovascular & haematological disorders.

Time‐dependent association between coagulation factor inactivation and increased elastase during experimental sepsis

J. Samis, K. Stewart, M. Nesheim, 2009, Journal of thrombosis and haemostasis : JTH.

Dependence of antithrombin III and thrombin binding stoichiometries and catalytic activity on the molecular weight of affinity-purified heparin.

K. Mann, M. Nesheim, M. Blackburn, 1986, The Journal of biological chemistry.

Differences in prethrombin-1 activation with human or bovine factor Va can be attributed to the heavy chain

M. Nesheim, P. Kim, R. Manuel, 2009, Thrombosis and Haemostasis.

Surface-dependent reactions of the vitamin K-dependent enzyme complexes

Kenneth G. Mann, Sriram Krishnaswamy, K. Mann, 1990 .

Surface-dependent reactions of the vitamin K-dependent enzyme complexes.

K. Mann, M. Nesheim, K G Mann, 1990, Blood.

The coagulant-active phospholipid content is a major determinant of in vivo thrombogenicity of prothrombin complex (Factor IX) concentrates in rabbits.

K. Mann, A. Giles, M. Nesheim, 1982, Blood.

Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism.

K. Mann, M. Nesheim, W. Church, 1987, The Journal of biological chemistry.

A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

M. Boffa, Wei Wang, M. Nesheim, 1998, The Journal of Biological Chemistry.

The Activation-resistant Conformation of Recombinant Human Plasminogen Is Stabilized by Basic Residues in the Amino-terminal Hinge Region (*)

A. Horrevoets, H. Pannekoek, M. Nesheim, 1995, The Journal of Biological Chemistry.

Mechanism of anticoagulant action by protein inhibitors from bovine testes and salmon sperm.

M. Nesheim, V. Doctor, A. Campbell, 1987, Thrombosis research.

Thrombin-Activated Human Factor V Human Neutrophil Elastase Activates Human Factor V but Inactivates

A. Giles, J. Samis, M. Nesheim, 2013 .

The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.

A. Horrevoets, H. Pannekoek, M. van Meijer, 1997, Blood.

The contribution of bovine Factor V and Factor Va to the activity of prothrombinase.

K. Mann, M. Nesheim, J. B. Taswell, 1979, The Journal of biological chemistry.

Circulating heparan sulfate proteoglycan anticoagulant from a patient with a plasma cell disorder.

K. Mann, E. Bowie, M. Nesheim, 1980, The Journal of clinical investigation.

Activated Thrombin-activatable Fibrinolysis Inhibitor Reduces the Ability of High Molecular Weight Fibrin Degradation Products to Protect Plasmin from Antiplasmin*

M. Nesheim, Mark Schneider, Michael Nesheim, 2004, Journal of Biological Chemistry.

A Study of the Protection of Plasmin from Antiplasmin Inhibition within an Intact Fibrin Clot during the Course of Clot Lysis*

M. Nesheim, Mark Schneider, Michael Nesheim, 2004, Journal of Biological Chemistry.

Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant‐active phospholipid

K. Mann, A. Giles, M. Nesheim, 1982, British journal of haematology.

Interaction of coagulation factor V and factor Va with platelets.

K. Mann, M. Nesheim, J. Peterson, 1979, The Journal of biological chemistry.

Isolation and characterization of single chain bovine factor V.

K. Mann, L. Hibbard, M. Nesheim, 1979, The Journal of biological chemistry.

Solulin increases clot stability in whole blood from humans and dogs with hemophilia.

D. Lillicrap, B. Sørensen, J. Foley, 2012, Blood.

Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation.

Ray C. Paton, M. Koschinsky, A. Giles, 2002, Blood.

Internal duplication and sequence homology in factors V and VIII.

K. Mann, R. Hewick, D. Fass, 1985, Proceedings of the National Academy of Sciences of the United States of America.

[21] Factor V

K. Mann, J. Katzmann, M. Nesheim, 1981 .

Thrombin-catalyzed activation of single chain bovine factor V.

K. Mann, M. Nesheim, 1979, The Journal of biological chemistry.

Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites*

P. Cook, J. Foley, M. Nesheim, 2011, The Journal of Biological Chemistry.

The Structural Integrity of Anion Binding Exosite I of Thrombin Is Required and Sufficient for Timely Cleavage and Activation of Factor V and Factor VIII*

T. Orban, M. Nesheim, P. Kim, 2006, Journal of Biological Chemistry.

Effect of a non-ionic surfactant, Merpol, on dye decolorization of Reactive blue 19 by laccase.

J. Ramsay, M. Nesheim, Paul-Philippe Champagne, 2010, Enzyme and microbial technology.

Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis

M. Boffa, Wei Wang, M. Nagashima, 1997, Thrombosis and Haemostasis.

Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein)

A. Horrevoets, H. Pannekoek, M. Nesheim, 1997, The Journal of Biological Chemistry.

Isolation of functional human coagulation factor V by using a hybridoma antibody.

K. Mann, L. Hibbard, J. Katzmann, 1981, Proceedings of the National Academy of Sciences of the United States of America.

Characterization of a stable form of human meizothrombin derived from recombinant prothrombin (R155A, R271A, and R284A).

D. Banfield, M. Nesheim, R. Macgillivray, 1994, The Journal of biological chemistry.

Identification of a congenital dysthrombin, thrombin Quick.

K. Mann, M. Nesheim, R. Henriksen, 1980, The Journal of clinical investigation.

THE ROLE OF FACTOR V IN THE ASSEMBLY OF THE PROTHROMBINASE COMPLEX *

K. Mann, L. Hibbard, M. Nesheim, 1981, Annals of the New York Academy of Sciences.

Fibrinolysis and the plasma carboxypeptidase

M. Nesheim, 1998, Current opinion in hematology.

A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.

M. Nesheim, Mark M. Schneider, R. Stewart, 2004, Analytical biochemistry.

A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor*

M. Boffa, M. Koschinsky, J. Hamill, 2002, The Journal of Biological Chemistry.

Criteria for specific measurement of plasminogen (enzymatic; procedure) in human plasma

J. Hoffmann, M. Nesheim, N. Booth, 2000, EJIFCC.

Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V.

A. Giles, J. Samis, M. Nesheim, 1997, Blood.

"Clotspeed," a mathematical simulation of the functional properties of prothrombinase.

K. Mann, R. Tracy, M. Nesheim, 1984, The Journal of biological chemistry.

Cofactor dependence of factor Xa incorporation into the prothrombinase complex.

K. Mann, E. Shaw, C. Kettner, 1981, The Journal of biological chemistry.

A rapid technique for the preparation of factor V deficient plasma.

K. Mann, J. Bloom, M. Nesheim, 1979, Thrombosis research.

Isolation of functional human coag hybridoma antibody (monoclonal antibody/affinity chromatography/Factor V activation/l

K. Mann, J. Katzmann, M. Nesheim, 2016 .

Phospholipid-binding properties of bovine factor V and factor Va.

K. Mann, J. Bloom, M. Nesheim, 1979, Biochemistry.

Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

Annette Lee, P. Gregersen, W. Robinson, 2011, The Journal of clinical investigation.

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.

M. Boffa, M. Koschinsky, J. Hamill, 2008, Blood.

Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells*

M. Boffa, M. Koschinsky, J. Hamill, 2003, The Journal of Biological Chemistry.

A mechanism for NaCl inhibition of Reactive Blue 19 decolorization and ABTS oxidation by laccase

J. Ramsay, M. Nesheim, Paul-Philippe Champagne, 2013, Applied Microbiology and Biotechnology.

Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

M. Boffa, M. Nesheim, W. Stevens, 2000, The Journal of Biological Chemistry.

Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties*

M. Boffa, Wei Wang, M. Nesheim, 1998, The Journal of Biological Chemistry.

Assembly of prothrombinase complex.

K. Mann, E. Pryzdial, M. Nesheim, 1993, Methods in enzymology.

The factor Xa-catalyzed activation of factor V.

K. Mann, M. Nesheim, W. Foster, 1983, The Journal of biological chemistry.

The interaction of fragment 1 of prothrombin with the membrane surface is a prerequisite for optimum expression of factor Va cofactor activity within prothrombinase

T. Orban, M. Nesheim, P. Kim, 2008, Thrombosis and Haemostasis.

Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara.

Gemma L. J. Fuller, S. Watson, R. Wait, 2006, Biochimica et biophysica acta.

Bovine alpha- and beta-thrombin. Reduced fibrinogen-clotting activity of beta-thrombin is not a consequence of reduced affinity for fibrinogen.

K. Mann, R. Lundblad, J. Jenzano, 1984, The Journal of biological chemistry.

Activation of Protein C and Its Distribution between Its Inhibitors, Protein C Inhibitor, α1-Antitrypsin and α2-Macroglobulin, in Patients with Disseminated intravascular Coagulation

M. Scully, M. Nesheim, H. Hoogendoorn, 1993, Thrombosis and Haemostasis.

a,-Macroglobulin Binds and Inhibits Activated Protein C

A. Giles, C. Toh, M. Nesheim, 2003 .

The p11 subunit of annexin II heterotetramer is regulated by basic carboxypeptidase.

D. Waisman, Kyu-Sil Choi, D. Fogg, 2002, Biochemistry.

An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.

J. Foley, M. Nesheim, P. Kim, 2008, Analytical biochemistry.

The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex*

A. Gils, M. Whitlow, P. Declerck, 2009, Journal of Biological Chemistry.

apoSAA and AA: Precursor and Product Revisited

M. Nesheim, R. Kisilevsky, C. Tape, 1988 .

Membrane penetration of bovine factor V and Va detected by labeling with 5-iodonaphthalene-1-azide.

K. Mann, M. Nesheim, C. Gitler, 1987, The Journal of biological chemistry.

Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAF1) with blood pressure.

B. Zinman, M. Boffa, M. Koschinsky, 2001, Clinical genetics.

The Factor V Activation Paradox*

T. Orfeo, K. Mann, S. Butenas, 2004, Journal of Biological Chemistry.

Down regulation of prothrombinase by activated protein C during prothrombin activation.

M. Nesheim, P. Kim, 2010, Thrombosis and haemostasis.

Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis*

J. Foley, M. Nesheim, P. Kim, 2008, Journal of Biological Chemistry.

Myocardial infarction and the balance between fibrin deposition and removal.

M. Nesheim, 2001, Italian heart journal : official journal of the Italian Federation of Cardiology.

Calcium Ion Modulation of Meizothrombin Autolysis at Arg-Asp and Catalytic Activity (*)

R. MacGillivray, M. Nesheim, W. Stevens, 1996, The Journal of Biological Chemistry.

Characterization of Factor V activation intermediates.

K. Mann, R. Hewick, M. Nesheim, 1984, The Journal of biological chemistry.

Activated thrombin activatable fibrinolysis inhibitor ( TAFIa ) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD

J. Foley, M. Nesheim, D. Owczarek, 2012 .

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.

Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis.

M. Boffa, M. Koschinsky, J. Hamill, 2008, Blood.

A. Horrevoets, H. Pannekoek, M. Nesheim, 1997, The Journal of Biological Chemistry.

Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

M. Nesheim, J. Willemse, D. Hendriks, 2009, Journal of Thrombosis and Haemostasis.

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases TAFIa level in patients with IBD.

J. Foley, M. Nesheim, D. Owczarek, 2012, Journal of Crohn's & colitis.

Activated thrombin‐activatable fibrinolysis inhibitor is generated in vivo at levels that can substantially affect fibrinolysis in chimpanzees in response to thrombin generation

M. Nesheim, P. Kim, H. Hoogendorn, 2008, Journal of thrombosis and haemostasis : JTH.

Kinetic Characterization of Tissue-Type Plasminogen Activator (t-PA) and t-PA Deletion Mutants

H. Pannekoek, M. Nesheim, H. Veerman, 1991, Thrombosis and Haemostasis.

UvA-DARE (Digital Academic Repository) A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]- and [Lys78] plasminogen activation by native tissue-type plasminigen activator and variants that lack either the finger of kringle-2 domain

A. Horrevoets, H. Pannekoek, M. Nesheim, 2022 .

A revisit of the two-form kinetic model of prothrombinase: A rebuttal.

M. Nesheim, P. Kim, 2012, Biophysical chemistry.

Evidence that the thrombin-catalyzed feedback cleavage of fragment 1.2 at Arg154-Ser155 promotes the release of thrombin from the catalytic surface during the activation of bovine prothrombin.

K. Mann, M. Nesheim, R. Jenny, 1988, The Journal of biological chemistry.